Biotech · Private company
Seagen Inc.
Track this companyFree. Adds Seagen Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2523 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials25
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerPHASE2 · RECRUITING · started Apr 7, 2025ClinicalTrials.gov NCT06809140 · fetched Nov 12, 2026
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerPHASE2 · RECRUITING · started Jun 24, 2024ClinicalTrials.gov NCT05775471 · fetched Nov 12, 2026
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaPHASE2 · RECRUITING · started Apr 17, 2024ClinicalTrials.gov NCT06377566 · fetched Nov 12, 2026
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 14, 2023ClinicalTrials.gov NCT05922904 · fetched Nov 12, 2026
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyPHASE2 · RECRUITING · started Sep 26, 2023ClinicalTrials.gov NCT05756569 · fetched Nov 12, 2026
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerPHASE2 · RECRUITING · started Jul 24, 2023ClinicalTrials.gov NCT05748834 · fetched Nov 12, 2026
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)PHASE2 · RECRUITING · started May 16, 2023ClinicalTrials.gov NCT05673928 · fetched Nov 12, 2026
- A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainPHASE2 · ACTIVE_NOT_RECRUITING · started May 9, 2023ClinicalTrials.gov NCT05892068 · fetched Nov 12, 2026
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 25, 2022ClinicalTrials.gov NCT05230810 · fetched Nov 12, 2026
- Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 2, 2022ClinicalTrials.gov NCT05239624 · fetched Nov 12, 2026
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaPHASE3 · RECRUITING · started Apr 14, 2022ClinicalTrials.gov NCT04685616 · fetched Nov 12, 2026
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 7, 2022ClinicalTrials.gov NCT05319873 · fetched Nov 12, 2026
- Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 21, 2021ClinicalTrials.gov NCT04700124 · fetched Nov 12, 2026
- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 2, 2021ClinicalTrials.gov NCT04457596 · fetched Nov 12, 2026
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaPHASE2 · RECRUITING · started Dec 4, 2020ClinicalTrials.gov NCT04587687 · fetched Nov 12, 2026
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 30, 2020ClinicalTrials.gov NCT04223856 · fetched Nov 12, 2026
- A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 10, 2020ClinicalTrials.gov NCT04225117 · fetched Nov 12, 2026
- Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 24, 2019ClinicalTrials.gov NCT03924895 · fetched Nov 12, 2026
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 12, 2018ClinicalTrials.gov NCT03755804 · fetched Nov 12, 2026
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 3, 2018ClinicalTrials.gov NCT03587844 · fetched Nov 12, 2026
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 1, 2016ClinicalTrials.gov NCT02734771 · fetched Nov 12, 2026
- Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin LymphomaPHASE2 · COMPLETED · started Aug 7, 2015ClinicalTrials.gov NCT02505269 · fetched Nov 12, 2026
- Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaPHASE1_PHASE2 · COMPLETED · started Oct 10, 2014ClinicalTrials.gov NCT02227199 · fetched Nov 12, 2026
- Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 12, 2013ClinicalTrials.gov NCT01920932 · fetched Nov 12, 2026
- SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 1, 2011ClinicalTrials.gov NCT01352520 · fetched Nov 12, 2026